Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 17 10 2018
revised: 09 11 2018
accepted: 12 11 2018
pubmed: 26 11 2018
medline: 30 5 2019
entrez: 26 11 2018
Statut: ppublish

Résumé

The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia. A cross-sectional study of 80 MF and 23 ET patients was performed. About 35% of anaemic MF patients had functional iron deficiency (FID) with transferrin saturation <20 and normal or elevated S-ferritin (<500 µg/L). In ET, FID was rare. In MF patients with FID, 70.6% were anaemic, vs 29.4% in patients without FID (P = 0.03). Hepcidin was significantly higher in MF patients with anaemia, including transfusion-dependent patients, 50.6 vs 24.4 µg/L (P = 0.01). There was a significant negative correlation between Hb and inflammatory markers in all MF patients: IL-2, IL-6 and TNF-α, (P < 0.01-0.03), LD (P = 0.004) and hepcidin (P = 0.03). These correlations were also seen in the subgroup of anaemic MF patients (Table ). Tsat correlated negatively with CRP (P < 0.001). Symptom burden was heavier in MF patients with FID, and MPN-SAF quality of life scores correlated with IL-6 and CRP. The inflammatory state of MF disturbs iron turnover, FID is common and contributes to anaemia development and impairment of QoL. Anaemic MF patients should be screened for FID.

Identifiants

pubmed: 30472746
doi: 10.1111/ejh.13198
doi:

Substances chimiques

Biomarkers 0
Cytokines 0
Inflammation Mediators 0
Ferritins 9007-73-2
Iron E1UOL152H7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-240

Subventions

Organisme : Nordic Study Group for Myeloproliferative Neoplasms (NMPN)

Informations de copyright

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Gunnar Birgegard (G)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Jan Samuelsson (J)

Department of Hematology, University Hospital Linkoping, Linkoping, Sweden.

Erik Ahlstrand (E)

Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Elisabeth Ejerblad (E)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Christian Enevold (C)

Institute for Inflammation Research, Copenhagen University Hospital, Copenhagen, Denmark.

Waleed Ghanima (W)

Department of Research, Østfold Hospital, Sarpsborg, Norway.

Hans Hasselbalch (H)

Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Claus H Nielsen (CH)

Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Håvar Knutsen (H)

Department of Hematology, Ullevål Hospital, Oslo, Norway.

Ole B Pedersen (OB)

Department of Clinical Immunology, Naestved Hospital, Naestved, Denmark.

Anders Sørensen (A)

Institute for Inflammation Research, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Björn Andreasson (B)

Hematology Section, Specialist Medicine, NU Hospital Group, Uddevalla, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH